We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Shares of Gilead Sciences Inc. surged over 4% in premarket trading on Wednesday following a solid fourth-quarter earnings ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

sNDA accepted for Priority Review Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed DXd antibody drug conjugate Treatment of adults with locally advanced or metastatic ...